Search clinical trials for: SKYRIZI™

Total 5810 results

AbbVie
PPD

Recruiting

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

Plaque Psoriasis | Crohn Disease | Psoriatic Arthritis | Other Conditions for Which Risankizumab is an FDA-approved Treatment

United States
Cairo University

Recruiting

A Comparative Study of Visual Outcome of Two Extended Depth of Focus Intraocular Lenses After Cataract Surgery

Visual To Compare the Visual Outcome Between AcrySof™ IQ Vivity™ and TECNIS Synergy™ Intraocular Lens (Model ZFR00V )

Egypt
King Abdulaziz University

Completed

Effect of Carriere® Motion™ Appliance on Airway Dimensions

Effect of Carriere® Motion™ Appliance on Pharyngeal Airway Dimensions | Effect of Carriere® Motion™ Appliance on Skeletal and Dental Measurements

Saudi Arabia
AbbVie

Completed

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

Healthy Volunteers

United States
Istituto Clinico Humanitas

Unknown

Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity (PSORIASI_RISA)

Psoriasis
AbbVie

Completed

Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

Healthy Volunteers

United States
AbbVie

Recruiting

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

Inflammatory Bowel Disease

Israel
AbbVie

Completed

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Psoriatic Arthritis
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

Japan
AbbVie

Completed

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

Healthy Volunteers

United States
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Healthy | Arthritis, Psoriatic

Austria
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (LIMMITLESS)

Psoriasis

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Sweden, Taiwan
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Technical University of Munich

Completed

Covering of the Abdominal Wall in Laparotomies: Differences in Surgical Site Infections Between an Approved Abdominal 3M™ Steri-Drape™ Wound Edge Protector and Standard Woven Swabs at Technische Universität München (BaFo)

Comparing the Number of Surgical Site Infections | Covering of the Abdominal Wall in Laparotomies With an Approved Abdominal 3M™ Steri-Drape™ Wound Edge Protector and Standard Woven | Swabs

Germany
AbbVie

Withdrawn

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Psoriasis
AbbVie

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Crohn's Disease

United States, Canada, Israel, Taiwan, Japan, Korea, Republic of
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Oregon Medical Research Center
AbbVie

Active, not recruiting

High Dose Risankizumab for Psoriasis (KNOCKOUT)

Psoriasis

United States
AbbVie

Completed

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Plaque Psoriasis

United States, Australia, Germany, Israel, Italy, Spain, Taiwan, United Kingdom
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
AbbVie

Completed

Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care (prIMMa)

Psoriasis

Israel
AbbVie

Completed

A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

Healthy Volunteers

China
AbbVie

Recruiting

An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK) (COMMODUS)

Crohn's Disease

United Kingdom
AbbVie

Recruiting

Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan

Psoriasis

Taiwan
University of Texas Southwestern Medical Center

Completed

Customized Laser Ablation: Comparing Results of LADAR Vision and VISX Platforms

Customized Laser Ablation

United States
AbbVie

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Korea, Republic of, Taiwan, Israel, Switzerland, United Kingdom, Puerto Rico
Aubrey Inc.

Unknown

Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery (AWBAT-D)

Treatment of Donor Site Burns

United States
UCB Biopharma S.P.R.L.

Completed

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

Parkinson´s Disease

United States
Columbia University

Completed

Clinical Investigation of an Eye-Tracking Device as a Predictor of Delirium in the Recovery Room After Surgery With General Anesthesia

Delirium

United States
Prince of Songkla University

Completed

Requirements of Propofol With Target Controlled Infusions for Supraglottic Airway Devices

Complication of Device Insertion | Appropriate Affect

Thailand
Cairo University

Unknown

Shade Evaluation of Monochromatic Versus Polychromatic Layering Techniques Inrestoration of Fractured Incisal Angle

Anterior Teeth
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
AbbVie

Active, not recruiting

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom
Genomind, LLC
Medpace, Inc.

Completed

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

Major Depressive Disorder

United States
Sanofi

Completed

Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age

Pertussis | Tetanus | Diphtheria | Poliomyelitis

Thailand
Deka Research and Development
CVS Kidney Care LLC.

Completed

An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System

End Stage Renal Disease

United States
AbbVie

Completed

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

Healthy Volunteers

United States
AbbVie

Completed

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

Healthy Volunteers

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

Japanese Encephalitis | Japanese Encephalitis Virus Disease

Korea, Republic of
Ception Therapeutics
Cephalon

Completed

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Asthma

United States, Canada
Merck KGaA, Darmstadt, Germany
Merck Ltd., Taiwan; Merck Pte. Ltd., Singapore; PT Merck Tbk., Indonesia, an...

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore) (ECOS TW ID SG)

Growth Disorders

Singapore, Taiwan, Indonesia
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines

Cholera

Philippines
GlaxoSmithKline

Completed

Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years

Hepatitis B | Hepatitis A

Belgium, Czech Republic
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Medtronic Neurovascular Clinical Affairs

Completed

Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study

Arteriovenous Malformations

United States
Federal University of São Paulo

Completed

A Comparative Study Minisling Versus Transobturator (TOT)Sling (sui)

Female Stress Urinary Incontinence

Brazil
Advanced Bionics

Completed

Evaluation of a HiRes™ Optima Sound Processing Strategy for the HiResolution™ Bionic Ear

Severe to Profound Hearing Loss | in Adult Users of Advanced Bionics HiResolution™ Bionic Ear System

United States
Jaehwan Kim
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Recruiting

Risankizumab Long-term Remission Study

Psoriasis

United States

3

Subscribe